Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Free Cash Flow (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Free Cash Flow for 10 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 33.08% to -$3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.4 million through Dec 2025, up 13.14% year-over-year, with the annual reading at -$19.4 million for FY2025, 13.14% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$3.2 million at Rein Therapeutics, up from -$3.5 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$1.6 million in Q3 2023, with the low at -$10.4 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$5.5 million, with a median of -$5.5 million recorded in 2022.
  • The sharpest move saw Free Cash Flow soared 76.47% in 2023, then crashed 169.22% in 2024.
  • Over 5 years, Free Cash Flow stood at -$6.3 million in 2021, then grew by 29.51% to -$4.4 million in 2022, then tumbled by 135.68% to -$10.4 million in 2023, then skyrocketed by 53.69% to -$4.8 million in 2024, then skyrocketed by 33.08% to -$3.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$3.2 million, -$3.5 million, and -$6.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.